nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.10.2013 | Infection (J Berger, Section Editor)

Update on HIV-Associated Neurocognitive Disorders

verfasst von: Tariq B. Alfahad, Avindra Nath

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

Neurocognitive disorders are a feared complication of HIV infection, especially in the post-antiretroviral era as patients are living longer. These disorders are challenging in terms of diagnosis and treatment. The clinical syndrome has evolved, driven in part by comorbidities such as aging, drug abuse, psychiatric illnesses, and a metabolic syndrome associated with the use of antiretroviral drugs. Additionally some individuals may develop a fulminant immune reconstitution syndrome. Hence, treatment of these patients needs to be individualized. The focus of research in the HIV field has recently switched towards elimination of the HIV reservoir as a means of combating long-term HIV complications. However, these approaches may be suitable for limited populations and might not be applicable once the HIV reservoir has been established in the brain. Further, all clinical trials using neuroprotective or anti-inflammatory drugs for treatment of HIV-associated neurocognitive disorders have been unsuccessful. Hence, neurological complications of HIV infection are the biggest challenge facing HIV researchers, and there is a critical need to develop new diagnostics and approaches for treatment of these disorders.

Tanne JH. Nearly 40 million people worldwide are infected with HIV. BMJ. 2006;332:1289.PubMedCrossRef

Hogan C, Wilkins E. Neurological complications in HIV. Clin Med. 2011;11(6):571–5.PubMedCrossRef

•• Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17:3–16. This study shows in a large multicenter cohort that the prevalence of HAND is still substantial despite adequate ART.PubMedCrossRef

Carey CL, Woods SP, Rippeth JD, et al. Prospective memory in HIV-1 infection. J Clin Exp Neuropsychol. 2006;28(4):536–48.PubMedCrossRef

Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59(12):1944–50.PubMedCrossRef

Cherner M, Masliah E, Ellis RJ, et al. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology. 2002;59:1563–7.PubMedCrossRef

Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–99.PubMedCrossRef

Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 2007;8(1):33–44.PubMedCrossRef

McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005;4(9):543–55.PubMedCrossRef

10.

Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17(1):3–16.PubMedCrossRef

11.

• Johnson T, Nath A. Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol. 2011;24(3):284–90. This review discusses the clinical manifestations, pathophysiology, and management of IRIS affecting the CNS in HIV-infected individuals.PubMedCrossRef

12.

Gonzalez E, Rovin BH, Sen L, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A. 2002;99:13795.PubMedCrossRef

13.

Valcour V, Shikuma C, Shiramizu B, et al. Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort. J Neuroimmunol. 2004;157:197–202.PubMedCrossRef

14.

Singh KK, Ellis RJ, Marquie-Beck J, et al. CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults. J Neuroimmunol. 2004;157:185–92.PubMedCrossRef

15.

Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375:1014–28.PubMedCrossRef

16.

McCutchan JA, Marquie-Beck JA, Fitzsimons CA, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology. 2012;78:485–92.PubMedCrossRef

17.

Valcour VG, Sacktor NC, Paul RH, et al. Insulin resistance is associated with cognition among HIV-1-infected patients: the Hawaii Aging with HIV Cohort. J Acquir Immune Defic Syndr. 2006;43:405–10.PubMedCrossRef

18.

McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS cohort study. Neurology. 1993;43:2245–52.PubMedCrossRef

19.

Becker JT, Kingsley L, Mullen J, et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology. 2009;73:1292–9.PubMedCrossRef

20.

Esiri MM, Biddolph SC, Morris CS. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry. 1998;65:29–33.PubMedCrossRef

21.

Rempel HC, Pulliam L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS. 2005;19:127–35.PubMedCrossRef

22.

• Achim CL, Adame A, Dumaop W, et al. Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol. 2009;4:190–9. This demonstrates that the amyloid based pathology in HIV infected individuals is distinctly different from that in Alzheimer’s disease.PubMedCrossRef

23.

Cherner M, Ellis RJ, Lazzaretto D, et al. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS. 2004;18 Suppl 1:S27–34.PubMed

24.

Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology. 2004;63:822–7.PubMedCrossRef

25.

Sacktor N, Skolasky R, Selnes OA, et al. Neuropsychological test profile differences between young and old human immunodeficiency virus-positive individuals. J Neurovirol. 2007;13:203–9.PubMedCrossRef

26.

Parsons TD, Tucker KA, Hall CD, et al. Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. AIDS. 2006;20:1591–5.PubMedCrossRef

27.

Tozzi V, Balestra P, Lorenzini P, et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol. 2005;11:265–73.PubMedCrossRef

28.

Sun B, Abadjian L, Rempel H, et al. Differential cognitive impairment in HCV coinfected men with controlled HIV compared to HCV monoinfection. J Acquir Immune Defic Syndr. 2013;62:190–6.PubMedCrossRef

29.

•• Nath A, Clements JE. Eradication of HIV from the brain: reasons for pause. AIDS. 2011;25(5):577–80. This article discusses the challenges in the eradication of HIV from the brain.PubMedCrossRef

30.

Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2008;105:3879–84.PubMedCrossRef

31.

Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007;3:e46.PubMedCrossRef

32.

Nath A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis. 2002;186 Suppl 2:S193–8.PubMedCrossRef

33.

Johnson TP, Patel K, Johnson KR, et al. Induction of IL-17 and non-classical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci USA. 2013. doi:10.1073/pnas.1308673110.

34.

Bruce-Keller AJ, Chauhan A, Dimayuga FO, et al. Synaptic transport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain. J Neurosci. 2003;23(23):8417–22.PubMed

35.

Wang T, Lee MH, Choi E, et al. Granzyme B-induced neurotoxicity is mediated via activation of PAR-1 receptor and Kv1. 3 channel. PLoS One. 2012;7(8):e43950.PubMedCrossRef

36.

Wang T, Allie R, Conant K, et al. Granzyme B mediates neurotoxicity through a G-protein-coupled receptor. FASEB J. 2006;20(8):1209–11.PubMedCrossRef

37.

Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One. 2008;3(6):e2516.PubMedCrossRef

38.

Kamat A, Ancuta P, Blumberg RS, et al. Serological markers for inflammatory bowel disease in AIDS patients with evidence of microbial translocation. PLoS One. 2010;5(11):e15533.PubMedCrossRef

39.

Dohgu S, Fleegal-DeMotta MA, Banks WA. Lipopolysaccharide-enhanced transcellular transport of HIV-1 across the blood-brain barrier is mediated by luminal microvessel IL-6 and GM-CSF. J Neuroinflammation. 2011;8(1):167.PubMedCrossRef

40.

Pang S, Koyanagi Y, Miles S, et al. High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients. Nature. 1990;343(6253):85–9.PubMedCrossRef

41.

Wu Y, Marsh JW. Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science. 2001;293(5534):1503–6.PubMedCrossRef

42.

Teo I, Veryard C, Barnes H, et al. Circular forms of unintegrated human immunodeficiency virus type 1 DNA and high levels of viral protein expression: association with dementia and multinucleated giant cells in the brains of patients with AIDS. J Virol. 1997;71(4):2928–33.PubMed

43.

Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23(11):1359–66.PubMedCrossRef

44.

Gray LR, Gabuzda D, Cowley D, et al. CD4 and MHC class 1 down-modulation activities of nef alleles from brain- and lymphoid tissue-derived primary HIV-1 isolates. J Neurovirol. 2011;17(1):82–91.PubMedCrossRef

45.

Dunfee RL, Thomas ER, Gorry PR, et al. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci U S A. 2006;103(41):15160–5.PubMedCrossRef

46.

Gonzalez-Perez MP, O'Connell O, Lin R, et al. Independent evolution of macrophage-tropism and increased charge between HIV-1 R5 envelopes present in brain and immune tissue. Retrovirology. 2012;9:20.PubMedCrossRef

47.

Cowley D, Gray LR, Wesselingh SL, et al. Genetic and functional heterogeneity of CNS-derived tat alleles from patients with HIV-associated dementia. J Neurovirol. 2011;17(1):70–81.PubMedCrossRef

48.

Li W, Huang Y, Reid R, et al. NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci. 2008;28(47):12190–8.PubMedCrossRef

49.

Olivieri KC, Agopian KA, Mukerji J, et al. Evidence for adaptive evolution at the divergence between lymphoid and brain HIV-1 nef genes. AIDS Res Hum Retrovir. 2010;26(4):495–500.PubMedCrossRef

50.

Thompson KA, Churchill MJ, Gorry PR, et al. Astrocyte specific viral strains in HIV dementia. Ann Neurol. 2004;56(6):873–7.PubMedCrossRef

51.

Lamers SL, Gray RR, Salemi M, et al. HIV-1 phylogenetic analysis shows HIV-1 transits through the meninges to brain and peripheral tissues. Infect Genet Evol. 2011;11(1):31–7.PubMedCrossRef

52.

Vissers M, Stelma FF, Koopmans PP. Could differential virological characteristics account for ongoing viral replication and insidious damage of the brain during HIV 1 infection of the central nervous system? J Clin Virol. 2010;49(4):231–8.PubMedCrossRef

53.

Lamers SL, Salemi M, Galligan DC, et al. Human immunodeficiency virus-1 evolutionary patterns associated with pathogenic processes in the brain. J Neurovirol. 2010;16(3):230–41.PubMedCrossRef

54.

Aquaro S, Calio R, Balzarini J, et al. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res. 2002;55(2):209–25.PubMedCrossRef

55.

Cinque P, Presi S, Bestetti A, et al. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid. AIDS Res Hum Retrovir. 2001;17(5):377–83.PubMedCrossRef

56.

Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010;18(2):45–55.PubMed

57.

• Cohen J. Understanding HIV latency to undo it. Science. 2011;332(6031):786. This reviews all the ongoing clinical trials for eradication of HIV infection.PubMedCrossRef

58.

Johnson T, Nath A. Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol. 2011;24(3):284–90.PubMedCrossRef

59.

Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. 2010;28(8):839–47.PubMedCrossRef

60.

Ene L, Duiculescu D, Ruta SM. How much do antiretroviral drugs penetrate into the central nervous system? J Med Life. 2011;4(4):432.PubMed

61.

Sawchuk RJ, Yang Z. Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Adv Drug Deliv Rev. 1999;39(1):5–31.PubMedCrossRef

62.

Croteau D, Letendre S, Best BM, et al. Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother. 2010;54(12):5156–60.PubMedCrossRef

63.

Dahl V, Lee E, Peterson J, et al. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis. 2011;204(12):1936–45.PubMedCrossRef

64.

Nowacek A, Gendelman HE. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine. 2009;4(5):557–74.PubMedCrossRef

65.

Rao KS, Reddy MK, Horning JL. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials. 2008;29(33):4429–38.PubMedCrossRef

66.

Tan IL, McArthur JC. HIV-Associated neurological disorders. CNS Drugs. 2012;26(2):123–34.PubMedCrossRef

Titel: Update on HIV-Associated Neurocognitive Disorders
verfasst von: Tariq B. Alfahad
Avindra Nath
Publikationsdatum: 01.10.2013
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 10/2013
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-013-0387-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Update on HIV-Associated Neurocognitive Disorders

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2013

Imaging the Role of GABA in Movement Disorders

Neurologic Complications of Infective Endocarditis

The Functional Anatomy of Impulse Control Disorders

Non-Lyme Tick-Borne Diseases: A Neurological Perspective

Episodic Movement Disorders: From Phenotype to Genotype and Back

Medication Nonadherence in Parkinson’s Disease

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie